Verrica Pharmaceuticals Inc.
VRCA
$5.23
-$0.12-2.24%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.70M | 7.18M | 7.57M | 9.21M | 13.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.70M | 7.18M | 7.57M | 9.21M | 13.91M |
| Cost of Revenue | 17.96M | 19.48M | 22.85M | 30.95M | 30.78M |
| Gross Profit | -3.26M | -12.30M | -15.28M | -21.74M | -16.88M |
| SG&A Expenses | 43.66M | 51.33M | 58.82M | 65.94M | 69.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.36M | 62.55M | 73.40M | 84.32M | 92.23M |
| Operating Income | -38.65M | -55.37M | -65.84M | -75.11M | -78.32M |
| Income Before Tax | -48.60M | -65.99M | -76.58M | -84.99M | -86.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -48.60 | -65.99 | -76.58 | -84.99 | -86.93 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -48.60M | -65.99M | -76.58M | -84.99M | -86.93M |
| EBIT | -38.65M | -55.37M | -65.84M | -75.11M | -78.32M |
| EBITDA | -37.95M | -54.53M | -64.88M | -74.19M | -77.52M |
| EPS Basic | -8.30 | -12.01 | -15.36 | -18.27 | -18.77 |
| Normalized Basic EPS | -5.18 | -7.50 | -9.59 | -11.08 | -11.39 |
| EPS Diluted | -8.30 | -12.02 | -15.36 | -18.27 | -18.77 |
| Normalized Diluted EPS | -5.18 | -7.50 | -9.59 | -11.08 | -11.39 |
| Average Basic Shares Outstanding | 30.38M | 25.55M | 20.71M | 18.61M | 18.54M |
| Average Diluted Shares Outstanding | 30.39M | 25.55M | 20.71M | 18.61M | 18.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |